Alle Nachrichten

Continued structuring to optimize supply and support the growth strategy - Appointment of Erwan Martin as Deputy Chief Executive Officer

Continued growth - Stable results - Strong embedded growth drivers - Issuance of straight bonds to finance future growth

SPINEWAY, a specialist in innovative implants for the treatment of severe spine disorders, is once again participating in the 2026 Annual Congress of the French Spine Surgery Society (SFCR), to be held from June 11 to 13 at the Palais du Pharo in Marseille.

High order volume / Slower-than-expected normalization of supply chains / 2026: growth trajectory confirmed

The Combined General Meeting (Ordinary and Extraordinary) of Spineway shareholders was held on first notice on Thursday 2 April 2026 at 10.00 am at the company’s registered office, 7 allée Moulin Berger in Ecully (69).

Le groupe Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), a organisé jeudi 19 mars un webinaire au cours duquel, Stéphane Le Roux, PDG de Spineway, et Erwan Martin, Directeur financier, ont présenté les résultats annuels 2025 et les perspectives du Groupe.

• Revenue up 4% • Improved results • Stronger growth potential

In the final quarter of 2025, Spineway, a specialist in innovative implants for the treatment of severe spine disorders, benefited from an acceleration in sales across all of its markets and the receipt of key account orders deferred from the first half of the year. With revenue of €3.8 million, up 34% compared with Q4 2024 (€2.8 million), Spineway recorded a particularly dynamic fourth quarter.

Spineway, a specialist in innovative implants for the treatment of spine disorders, announces the commercial launch of its VEOS and Twin Peaks ranges in Colombia.